Clinical Scorecard: Assessing the Vulnerability of Evidence Supporting Anti-Fracture Treatment Efficacy
At a Glance
Category
Detail
Condition
Osteoporosis and fracture prevention
Key Mechanisms
Pharmacological interventions aimed at reducing fracture risk
Target Population
Patients at risk of fractures, typically with osteoporosis
Care Setting
Clinical settings managing osteoporosis and fracture prevention
Key Highlights
Fragility Index (FI) quantifies the minimum number of event status changes needed to nullify statistical significance in RCTs.
Median FI across 27 RCTs was 9, indicating high fragility of anti-fracture efficacy evidence.
Romosozumab showed the most robust evidence (FI median 19.5), while denosumab and calcium/vitamin D showed more fragile evidence.
Guideline-Based Recommendations
Diagnosis
Use randomized controlled trials with fracture outcomes as primary endpoints to assess anti-fracture efficacy.
Management
Incorporate Fragility Index and Fragility Quotient alongside P values when evaluating anti-fracture treatment efficacy.
Prefer pharmacological interventions with higher FI values indicating more robust evidence.
Monitoring & Follow-up
Monitor loss to follow-up closely as it often exceeds the Fragility Index, potentially impacting evidence robustness.
Risks
Be cautious interpreting results with P values near 0.05 due to potential fragility and misinterpretation of efficacy.
Recognize that small changes in event counts can shift statistical significance, affecting clinical decisions.
Patient & Prescribing Data
Patients enrolled in phase 3/4 RCTs assessing anti-fracture pharmacological interventions
Evidence robustness varies by intervention; romosozumab has the strongest anti-fracture efficacy evidence, while denosumab and calcium/vitamin D supplementation show more fragile results.
Clinical Best Practices
Evaluate both P values and Fragility Index/Quotient when interpreting RCT results for anti-fracture treatments.
Communicate the fragility of evidence to patients during risk-benefit discussions.
Consider the number of participants lost to follow-up relative to the Fragility Index when assessing study reliability.
Prioritize treatments supported by RCTs with fractures as primary endpoints and highly significant P values (<0.001).
